74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
O Oxford Biomedica PLC
O
Closed
343.5 -8.28
Overview
Share price change
24h
Min
336.5
Max
350
Income | -32M |
|---|---|
Sales | 51M |
Profit margin | -63.939 |
Employees | 834 |
EBITDA | -20M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +67.05 upside |
Next Earnings | 28 Apr 2025 |
|---|
Market Cap | 407M |
|---|---|
Previous open | 351.78 |
Previous close | 343.5 |
Oxford Biomedica PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Oxford Biomedica PLC Forecast
Price Target
By TipRanks
67.05% upside
12 Months Forecast
Average 576.314 GBX 67.05%
High 740 GBX
Low 490 GBX
Based on 3 Wall Street analysts offering 12 month price targets forOxford Biomedica PLC - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Oxford Biomedica PLC
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.